The Hope for Oral Delivery of Biologics for DDE business

White Papers of Drug Delivery  – Part 1/3
Christopher A. Rhodes (Ph.D), President & CEO of DDE Labs, Inc.
06 September 2019

  Drug Delivery Technologies have been evolving with the development of pharmaceutics and biologics. 
  With these 3 articles, Dr. Christopher Rhodes, CEO of DDE Labs,  describes the development and the frontline of Drug Delivery.
This is Part 1 of a Series of 3 segments.

(Table of content)
Part 1
    - The Hope for Oral Delivery of Biologics
Part 2
    - Renewed Interest in Long-Acting Injectable and Implantable Drug Products
Part 3
    - The Challenges of Complex Generics

Keywords for the article: Drug Delivery, Oral Delivery, Injectable, Implantable, Long-acting systems,


The Hope for Oral Delivery of Biologics

  The hope has been that biologics injectable products could be converted to oral therapies in the form of a tablet or capsule.  This would greatly expand the utilization by patients and physicians, and in turn the market potential for these already valuable injectable products. In addition, from a product support perspective, patients know what to do with an oral tablet or capsule and require no training.  On the other hand, injectable systems require training prior to use and ongoing technical support, which can be quite significant costs for commercial pharmaceutical organizations.